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Introduction 
“When you become a person of pain, you will start on a journey 
that you will never forget and one of permanent change. The 
change that is thrust upon you will be unwanted, unpredictable, 
filled with uncertainty, and one that will be very destructive to 
your life if you do not take steps [to] control what will quickly 
become [an] out of control situation.” 1 
Beginning in the late 1990s, the United States began to feel the 
effects of what has recently been declared a “public emergency” by the 
Department of Health and Human Services – the opioid epidemic.2 The 
Government believed that the increase in opioid misuse, abuse, and 
 
1. Testimonials, CHRONIC PAIN, http://www.thechronicpain.com/ 
testimonials-1 (last visited Nov. 11, 2017) (citing a testimonial by Thomas 
Porter). 
2. What is the U.S. Opioid Epidemic?, U.S. DEP’T HEALTH & HUM. SERVS., 
https://www.hhs.gov/opioids/about-the-epidemic/index.html (last 
visited Feb. 17, 2019). 
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overdose was directly related to the number of opioid prescriptions 
written by doctors.3 State legislatures then responded by passing laws 
that imposed strict prescribing limitations and harsh punishment for 
those doctors that broke the law and disregarded the newly set 
limitations.4 As a result, doctors became fearful of creating addicts and 
breaking the law. Thus began the decline in the practice of prescribing 
opioids, even for those who suffered from chronic pain.5 
Meet Judy – a seventy-three-year-old, two-time cancer survivor.6 In 
2008, Judy was diagnosed with esophageal cancer. To combat the 
advanced-stage cancer, she underwent surgery to remove the cancerous 
portion of her esophagus. She then held tough through rounds upon 
rounds of chemotherapy. As a result, Judy suffered from severe chronic 
pain. To help, Judy’s oncologist prescribed OxyContin, a narcotic pain 
reliever that is used to treat moderate to severe pain.7 Though she took 
it as prescribed, as time went on, she needed to take more pills to 
achieve the same amount of pain relief. Then, it happened again. Two 
years later, after beating esophageal cancer, Judy was diagnosed with 
liver cancer. She, again, endured multiple rounds of chemotherapy. As 
a result of the pain she suffered, Judy’s oncologist prescribed more 
OxyContin. She continued to take the drug as directed, but continually 
required a higher dose to achieve adequate pain relief. Thankfully, Judy 
has been in remission since 2011. However, one effect of the cancers has 
 
3. Evan D. Anderson & Corey S. Davis, Breaking the Cycle of Preventable 
Suffering, 24 TEMP. INT’L & COMP. L.J. 329, 359-60 (2010). 
4. See e.g., ALASKA STAT. § 08.36.355 (2018) (enacted 2017); ALASKA STAT. 
§ 08.36.315 (2018) (enacted 2017); H.B. 333, 2017 Gen. Assemb., Reg. 
Sess. (Ky. 2017); N.J. ADMIN CODE § 13:45H-7.5 (2019) (enacted 2012); 
N.J. ADMIN CODE § 13:45H-7.20 (2019) (enacted 2013); Act 122, 2016 
Gen. Assemb., Reg. Sess. (Pa. 2016); Act 125, 2016 Gen. Assemb., Reg. 
Sess. (Pa. 2016); Amy J. Dilcher, Damned If They Do, Damned If They 
Don’t: The Need for a Comprehensive Public Policy to Address the 
Inadequate Management of Pain, 13 ANNALS HEALTH L. 81, 104-05 (2004); 
Ashley Bruce Trehan, Fear of Prescribing: How the DEA is Infringing 
on Patients’ Right Palliative Care, 61 U. MIAMI L. REV. 961, 976 
(2007). 
5. See Dilcher, supra note 4, at 85; Rima J. Oken, Curing Healthcare 
Providers’ Failure to Administer Opioids in the Treatment of Severe 
Pain, 23 CARDOZO L. REV. 1917, 1923 (2002). 
6. The information included in this paragraph comes from an interview 
conducted with my maternal grandmother. She does not wish for any 
other identifying information to be included in the article. 
7. OxyContin, DRUGS, https://www.drugs.com/oxycontin.html (last visited 
Mar. 19, 2018). 
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not subsided – the pain. To this day, Judy suffers from chronic pain 
and continually needs OxyContin.8 
Recently, the Pennsylvania legislature has taken steps to restrict 
opioid prescribing practices. In particular, Pennsylvania issued 
prescribing guidelines that recommended 100 mg per day as the 
maximum dose.9 Judy’s doctor, in response to the guideline publication 
and fear of scrutiny, informed Judy that he would have to decrease the 
amount of OxyContin she receives. For Judy, this was frightening 
because 100 mg was not enough and Judy now struggles to find a way 
to adequately treat her chronic pain. 
Unfortunately, Judy is not alone; approximately fifty million 
Americans suffer from chronic pain.10 If access to opioid pain medication 
is continually restricted or eliminated as a result of attempts to combat 
the opioid epidemic, there can be devastating consequences for chronic 
pain patients.11 It is time that the government reexamine its views on 
the opioid epidemic and how to end it. Chronic pain patients are 
unintentionally bearing the burden of new restrictive legislation. 
Therefore, there is a heightened need for a centrally coherent and 
comprehensive public health solution that addresses substance abuse, 
while at the same time providing chronic pain patients with the relief 
they need.12 Until a comprehensive strategy is implemented that reduces 
harm while allowing providers to care for patients without undue 
interference, chronic pain patients, rather than opioid abusers, will be 
 
8. Author’s interview with Judy Craday, in Corry, Pennsylvania (January 
2018). 
9. OPIOID DISPENSING GUIDELINES, COMMONWEALTH OF PA. & THE PA. 
PHARMACISTS ASS’N (2016), available at http://www.health.pa.gov/ 
My%20Health/Diseases%20and%20Conditions/AD/Documents/PA%20
Guidelines,%20on%20the%20Dispensing%20of%20Opioids.pdf. 
10. Chuck Weber, NIH Study Shows Prevalence of Chronic or Severe Pain in 
U.S. Adults, AM. PAIN SOC’Y (Aug. 18, 2015), 
http://americanpainsociety.org/ about-us/press-room/nih-study-shows-
prevalence-of-chronic-or-severe-pain-in-u-s-adults. 
11. Kent Durning, No Pain No Gain?! Who Will Make the Greatest Sacrifices 
in Curbing Opioid Analgesic Diversion and Abuse?, 93 KY. L.J. 199, 239 
(2004-05). 
12. See Tessa Cheng & Kora DeBeck, Between a Rock and a Hard Place: 
Prescription Opioid Restrictions in the Time of Fentanyl and Other Street 
Drug Adulterants, 108 CAN. J. PUB. HEALTH 325, 326 (2017). 
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the ones most affected by the government’s attempt to combat the 
opioid epidemic.13 
This Note will focus on restoring physician discretion and patient 
autonomy by proposing a uniform Prescription Drug Monitoring 
Program (“PDMP”) that may be adopted by state governments. If 
adopted, a uniform PDMP will allow doctors to use their best judgment 
when treating chronic pain patients while combatting the opioid 
epidemic. 
Part I of this Note will discuss the timeline and relevant statistics 
surrounding the opioid epidemic that has overwhelmed the United 
States in recent decades and the negative effects that the epidemic has 
had on the treatment of chronic pain patients. Part II will discuss the 
components of a PDMP and argue that a PDMP is the best approach 
to combat the opioid epidemic while restoring physician discretion and 
patient autonomy. Part III will discuss the current issues surrounding 
state PDMPs, including: (1) failure to collect sufficient data; (2) failure 
to effectively use collected data; (3) failure to distribute data across 
state lines; and (4) consequences of improperly structured PDMPs. Part 
III will also propose a uniform PDMP which incorporates the solutions 
to the outlined problems. 
I. The Opioid Epidemic and Its Effect on Chronic 
Pain Patients 
A. The Driving Force of Stringent Government Regulations – Opioids 
and The Opioid Epidemic 
Opioids are a class of drugs that includes synthetic opioids14 such 
as heroin and oxycodone that are legally obtainable via prescription.15 
Opioids work by chemically interacting with opioid receptors in the 
body and brain, thus producing euphoria in addition to pain relief. 
 
13. Sarah Ruiz-Grossman, America’s Drug Overdose Death Rate Keeps 
Getting Worse: CDC, HUFFINGTON POST (Nov. 7, 2017, 6:57 PM), 
https://www.huffpost.com/entry/drug-overdose-death-rate-rise-2016-
cdc_n_5a0211d3e4b06ff32c940276; Robert J. Gatchel, Is Fear of 
Prescription Drug Abuse Resulting in Sufferers of Chronic Pain Being 
Undertreated, 10 EXPERT REV. NEUROPATHICS 637 (2014). 
14. Synthetic opioids are narcotic analgesic drugs that are manufactured in 
chemical laboratories with a similar chemical structure to natural opiate 
drugs. Natural opiates are harvested from poppies, and contain alkaloids 
which have an analgesic effect. Synthetic opioids are manufactured using 
chemicals other than opium-related alkaloids. Synthetic Opioids, 
WORKPLACE TESTING, https://www.workplacetesting.com/definition/ 
3734/synthetic-opioids (last visited Mar. 15, 2018). 
15. Opioids, NAT’L INST. DRUG ABUSE, https://www.drugabuse.gov/drugs-
abuse/opioids. (last visited Nov. 15, 2017). 
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Opioids are, generally thought of as highly addictive.16 But, opioid pain 
relievers such as oxycodone, hydrocodone, codeine, and morphine, are 
usually safe when taken as prescribed.17 However, opioids have been 
misused, abused, and causing death for decades. The United States is, 
and has been since the late 1990s, in the midst of an opioid crisis.18 In 
fact, over the last decade, deaths attributable to synthetic opioid 
overdoses have risen from approximately 3500 to 28,400.19 As a result, 
the Center for Disease Control has declared the opioid crisis an 
“epidemic.”20 
In response, the Government began implementing legislation to 
limit the number of opioids prescribed to patients across the country. 
Though cracking down on prescribing practices of well-intentioned 
physicians is not the best method to combat the opioid epidemic, the 
government’s approach is not illogical. Beginning in 1991, the United 
States saw a sharp increase in the number of opioid prescriptions 
written by prescribers21 That year, “doctors wrote 76 million 
prescriptions” for opioid painkillers, and “[b]y 2011, that number had 
nearly tripled, to 219 million.”22 These figures troubled lawmakers 
because during that time, the population of the United States increased 
by sixteen percent and the amount of prescriptions written for some 
opioids increased by over 1000%.23 In 2012, the doctors in twelve states 
wrote more opioid prescriptions than the total number of patients 
 
16. Nancy R. Steer & Mollie A. Gass, Monitoring Controlled Substances: 
Prescription Monitoring Programs as a Tool for Monitoring the 
Prescription Drug Epidemic, 5 IN-HOUSE DEF. Q. 5, 6 (2016). 
17. COMMONWEALTH OF PA & THE PA PHARMACISTS ASS’N, supra note 9. 
18. CDC Fifty-State Survey of Doctor Shopping Laws and Patient 
Prescription Abuse, MED. RISK L. (Nov. 16, 2017), 
http://medicallawperspectives.com/Content_Weekly/CDC-Fifty-State-
Survey-of-Doctor-Shopping-Laws-and-Patient-Prescription-Abuse.aspx 
[hereinafter CDC Fifty-State Survey]; Dan Nolan & Chris Amico, How 
Bad is the Opioid Epidemic?, PBS (Feb. 23, 2016), https://www.pbs.org/ 
wgbh/frontline/article/how-bad-is-the-opioid-epidemic/. 
19. Overdose Death Rates, NAT’L INST. DRUG ABUSE (Sept. 2017), 
https://www.drugabuse.gov/related-topics/trends-statistics/overdose-
death-rates. 
20. Nolan & Amico, supra note 18. 
21. Id. 
22. Id. 
23. The statistics included in the article were from 1997 to 2011. The statistics 
pertained to oxycodone sold by retail pharmacies. Nancy A. Melville, 
Millions of Opioid Prescriptions Go to ‘Doctor Shoppers’, MEDSCAPE 
(July 23, 2013), https://www.medscape.com/viewarticle/808266. 
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treated; averaging more than one prescription per patient.24 Most 
recently, in 2015, approximately 250 million prescriptions were written 
for opioid painkillers which: (1) were enough for every American to be 
medicated twenty-four hours a day for three weeks; and (2) further 
solidified the United States’ position as the top consumer of opioids by 
exceeding the per capita rate of other countries.25 
Because opioids are regularly prescribed in the United States, the 
rise in prescription painkiller misuse is often attributed to the increasing 
supply and availability.26 Recent statistics show that there has been an 
increase in the number of non-medical uses of opioid pain relievers. 
Specifically, in 2010 study conducted by the National Household Survey 
on Drug Abuse, about seven million people aged twelve and older 
reported recreational use of prescription opioid pain relievers and that 
number increased to 16.7 million in 2012.27 
The sharp increase in opioid prescription painkiller misuse and 
abuse is frightening because these practices often lead to drug overdoses 
 
24. The calculations looked at how many prescription opioids were prescribed 
per 100 people. The following twelve states prescribed more than 100 
prescriptions per 100 people (in order of severity): Alabama, Tennessee, 
West Virginia, Kentucky, Oklahoma, Mississippi, Louisiana, Arkansas, 
Indiana, Michigan, South Carolina, and Ohio. Nolan & Amico, supra note 
18. 
25. The United States regularly consumes about 80% of the world’s opioids 
which renders it the top opioid consumer in the world. See Elaine Cox, 
The Hidden Victims of Opioid Epidemic, U.S. NEWS (June 22, 2017), 
https://health.usnews.com/health-care/for-better/articles/2017-06-
22/the-hidden-victims-of-the-opioid-epidemic; White House Comm’n on 
Combatting Drug Addiction and the Opioid Crisis, Draft Comm’n Interim 
Report (2017), available at https://www.whitehouse.gov/sites/ 
whitehouse.gov/files/ondcp/commission-interim-report.pdf [hereinafter 
White House Comm’n]; Opioid Crisis: Five Ways to Tackle the U.S. Drug 
Epidemic, BBC NEWS (Aug. 6, 2017), http://www.bbc.com/news/world-
us-canada-40479686. 
26. Steer & Gass, supra note 16; Increased Drug Availability is Associated 
with Increased Use and Overdose, NAT’L INST. DRUG ABUSE, 
https://www.drugabuse.gov/publications/research-reports/relationship-
between-prescription-drug-abuse-heroin-use/increased-drug-availability-
associated-increased-use-overdose (last updated Jan. 2018). 
27. RESULTS FROM THE 2010 NATIONAL SURVEY ON DRUG USE AND HEALTH: 
SUMMARY OF NATIONAL FINDINGS, U.S. DEP’T OF HEALTH & HUM. 
SERVICES (Sept. 2011), available at https://www.samhsa.gov/data/ 
sites/default/files/NSDUHNationalFindingsResults2010-web/ 
2k10ResultsRev/NSDUHresultsRev2010.pdf. 
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and quite possibly death.28 In recent years, prescription opioids have 
been a driving-force in the fifteen-year increase in opioid overdose 
deaths.29 Currently, forty-six people in the United States die every day 
as a result of prescription opioid overdoses; those deaths constitute 
about thirty-five percent of all overdose deaths annually.30 The 
relationship between the increase in supply, misuse, and overdose 
deaths seems to point to prescribers as the culprits, and at first glance 
it seems sensible to restrict prescribers’ decision-making power. But, 
what the government may not have considered when passing new 
restrictive legislation was the effect it would have on those who need 
access – chronic pain patients. 
B. (Under)Treatment of Chronic Pain Patients and How the Opioid 
Epidemic Has Affected Their Treatment 
1. Undertreatment of Chronic Pain Patients Unrelated to the Effects of 
the Opioid Epidemic 
Chronic pain is the “most common and debilitating disorder” in the 
United States.31 It affects one-third of Americans at some point in their 
lives and is the most common cause of long-term disability.32 Chronic 
 
28. David Blumenthal & Shanoor Seervai, To Combat the Opioid Epidemic, 
We Must Be Honest About Its Causes, HARV. BUS. REV. (Oct. 26, 2017), 
https://hbr.org/2017/10/to-combat-the-opioid-epidemic-we-must-be-
honest-about-all-its-causes. 
29. See Kristin Finklea et al., Prescription Drug Monitoring Programs, CONG. 
RESEARCH SERV. (May 24, 2014), https://fas.org/sgp/crs/misc/ 
R42593.pdf (“Nearly three out of four prescription drug overdoses are 
caused by prescription painkillers or opioids”); Prescription opioid 
overdoses are now twice as common as heroin and cocaine deaths 
combined. See Melville, supra note 23. In 2011, 16,917 deaths were caused 
by overdoses involving prescription opioids. The number of overdose 
deaths jumped to 33,000 in 2015 with prescription opioid overdoses 
contributing to more than half the total. The death total then increased 
again in 2016 to anywhere between 59,000-65,000 with prescription 
opioids accounting for 40-50% of the death total. CDC Fifty-State Survey, 
supra note 18; Understanding the Epidemic, CTR. DISEASE CONTROL & 
PREVENTION, https://www.cdc.gov/drugoverdose/epidemic/index.html 
(last updated Dec. 19, 2018). 
30. Prescription Opioid Data¸ CTR. DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/drugoverdose/data/prescribing.html (last updated 
Dec. 19, 2018); Understanding the Epidemic, supra note 29. 
31. Bhavani S. Reddy, The Epidemic of Unrelieved Chronic Pain: The 
Ethical, Societal, and Regulatory Barriers Facing Opioid Prescribing 
Physicians, 27 J. LEGAL MED. 427, 430 (2006). 
32. Section 1: Background and Significance, AM. PAIN SOC’Y, 
http://americanpainsociety.org/uploads/education/section_1.pdf (last 
visited Feb. 16, 2019). 
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pain is defined as pain that continues beyond what was originally 
thought to be the “expected healing time of an injury or illness.”33 
Traditionally, severe pain that lasts for more than six months has been 
categorized as “chronic.” Medical professionals have, however, 
determined that a chronic pain diagnosis may be handed down as early 
as two to four weeks from the initial onset of pain.34 An individual 
coping with chronic pain may suffer from such severe and debilitating 
pain that it takes a toll on the patient’s relationships and day-to-day 
activities.35 If pain is left untreated, the individual may experience 
depression, or loss of employment, spouse, family, and even a loss of life 
if the patient commits suicide as a result of the chronic pain.36 In 
contrast, when a patient’s pain is appropriately controlled and treated, 
he or she is expected to experience an enhanced quality of life, increased 
physical functionality, and an improvement in general overall health.37 
Unfortunately, chronic pain is often undiagnosed and even when 
diagnosed, it is generally undertreated.38 
It is estimated that between forty-eight and fifty million Americans 
suffer from chronic pain and that those individuals visit physicians’ 
offices approximately ninety million times a year seeking medical care 
for their pain.39 As the population rises, the number of people who will 
need treatment for chronic pain is expected to rise.40 Unfortunately for 
those seeking palliative care,41 there is a significant public health 
problem surrounding the undertreatment of pain.42 Despite the fact that 
 
33. Reddy, supra note 31, at 427. 
34. Id.; Gregory Minnis, What Is Back Pain?, HEALTHLINE (Jan. 16, 2019), 
https://www.healthline.com/health/back-pain. 
35. Reddy, supra note 31, at 431. 
36. Id. at 432. 
37. Id. 
38. PAIN: CURRENT UNDERSTANDING OF ASSESSMENT, MANAGEMENT, AND 
TREATMENTS, NATIONAL PHARMACEUTICAL COUNCIL at 3 (Dec. 2001), 
available at http://americanpainsociety.org/uploads/education/ 
section_1.pdf. 
39. The number of chronic pain patients is expected to double by the year 
2030 because people are expected to live longer. See Reddy, supra note 
31, at 430; Beth Packman Weinman, Freedom from Pain, Establishing a 
Constitutional Right to Pain Relief, 24 J. LEGAL MED. 495, 503 (2003). 
40. AM. PAIN SOC’Y, supra note 32, at 3. 
41. Palliative care is different than curative treatment. It is primarily aimed 
at treating symptoms. See What are Palliative Care and Hospice Care?, 
NAT’L INST. AGING, https://www.nia.nih.gov/health/what-are-palliative-
care-and-hospice-care (last updated May 17, 2017). 
42. Oken, supra note 5, at 1931; Durning, supra note 11, at 215-19. 
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physicians have the requisite knowledge and resources to manage pain 
in an estimated ninety percent of individuals suffering from chronic 
pain,43 it is estimated that more than forty to fifty percent of chronic 
pain patients in routine practice settings fail to receive adequate pain 
relief for their condition.44 
The staggering numbers of undertreated patients may be attributed 
to the failure to incorporate prescription opioids into chronic pain 
treatment programs. In a recent survey, thirty-four percent of 
physicians believe that moving away from powerful painkillers such as 
opioids may be prolonging patients’ misery and harming those with 
chronic pain issues.45 Despite the negative implications raised by the 
opioid crisis, opioids and other pain-reducing medications still play an 
important role in managing patient’s chronic pain.46 Prescribers often 
view opioids as “the most effective, and often the only, treatment that 
provides significant relief for most patients suffering from chronic 
pain.”47 But, even though opioids have been essential for pain treatment 
for thousands of years, and many medical professionals view 
prescription opioids as a preferable, acceptable, and standard form of 
treatment for chronic pain patients, opioids have proven to be grossly 
underutilized in chronic pain management.48 
Failure to manage a patient’s pain creates harmful consequences 
and causes significant suffering.49 Individuals with untreated pain may 
suffer from serious mental complications, such as “anxiety, fear, anger, 
[and] depression;” “impair[ed] recovery from injury or procedures;”50 
and decreased quality of life, functionality, activity, appetite, and 
productivity.51 Take the story of fifty-three-year-old Doug Hale, for 
 
43. AM. PAIN SOC’Y, supra note 32, at 3. 
44. Christine E Whitten et al., Treating Chronic Pain: New Knowledge, More 
Choices, 9 PERMANENTE J. 9 (2005); Myra Glajchen, Chronic Pain: 
Treatment Barriers and Strategies for Clinical Practice, 14 J. AM. BOARD 
FAM. PRACTICE 211, 211 (2001). 
45. Happening Now: Are Doctors Harming Patients by Cutting Back on 
Prescription Painkillers?, FOX NEWS, (Jan. 6, 2017), 
https://www.foxnews.com/ health/happening-now-are-doctors-harming-
patients-by-cutting-back-on-prescription-painkillers. 
46. Gatchel, supra note 13. 
47. Durning, supra note 11, at 221; Reddy, supra note 31, at 428. 
48. Reddy, supra note 31, at 428. 
49. AM. PAIN SOC’Y, supra note 32, at 3. 
50. Id.; see Reddy, supra note 31, at 430. 
51. See Reddy, supra note 31, at 431. 
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example.52 Mr. Hale suffered from interstitial cystitis, severe migraines, 
and a back condition.53 He was prescribed methadone and oxycodone in 
2001 and continued to take the medication until his untimely death.54 
During his treatment, Mr. Hale’s physician eventually told Mr. Hale 
that he did not want to risk his medical license and, therefore, he could 
no longer provide Mr. Hale with his pain medication.55 Mr. Hale suffered 
for six weeks while attempting to find another doctor to treat his pain 
– those six weeks without pain medication drove Mr. Hale to suicide.56 
Similarly, Hailey Weeks met an untimely death due to a lack of 
chronic pain treatment. Ms. Weeks injured her back at age thirty-five 
and never recovered.57 She received opioids and sedatives to help with 
the pain, but when her doctor retired, she was left “with a one-month 
prescription and a list of doctors” to call.58 When those doctors refused 
to treat her, Ms. Weeks decided to try to wean herself off the 
medication.59 As a result, Ms. Weeks hastened her alcohol abuse, which 
lead to a trip to the emergency room, and then found herself in jail, 
where she eventually died.60 
Lastly, consider the story of Jean Karchefsky – a sixty-three-year-
old retired school bus driver.61 Ms. Karchefsky’s doctor told her that he 
would no longer treat her longstanding chronic pain resulting from disk 
and bone degeneration in her neck and spine.62 Unable to find a new 
doctor willing to renew her prescription, Ms. Karchefsky has suffered 
for months, going through withdrawal and with pain that leaves her 
vulnerable to nausea, anxiety, and insomnia.63 
 
52. Stefan Kertesz & Sally Satel, Some People Still Need Opioids, SLATE 
(Aug. 17, 2017, 3:53 PM), https://slate.com/technology/2017/08/ 
cutting-down-on-opioids-has-made-life-miserable-for-chronic-pain-
patients.html. 
53. Id. 
54. Id. 
55. Id. 
56. Id. 
57. Id. 
58. Id. 
59. Id. 
60. Id. 
61. Brie Zeltner, Suffering and Abandoned: Chronic Pain Patients Cut Off in 
the Opioid Era, CLEVELAND, https://www.cleveland.com/healthfit/ 
index.ssf/2018/04/suffering_and_abandoned_chroni.html (last updated 
Oct. 19, 2018). 
62. Id. 
63. Id. 
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In addition to psychological suffering, chronic pain may also prove 
difficult for the patient to maintain employment and engage in what 
most would consider daily activities.64 Difficulty maintaining 
employment is unfortunately all too common for those who suffer from 
unrelieved chronic pain. Chronic pain patients collectively use about 
fifty million sick days per year, which renders chronic pain “the second 
leading cause of medically related absenteeism and lost productivity in 
the workplace.”65 Additionally, forty-two percent of those with chronic 
pain report such severe pain that they are incapable of working.66 For 
example, if an individual is a laborer, the physical limitations caused 
by chronic pain may impair his or her ability to maintain employment.67 
Even if the individual works a sedentary job, pain may impair his or 
her concentration and make it difficult to complete necessary tasks.68 
Simply sitting for a long period of time or tilting one’s head to view a 
computer screen may become impossible due to chronic pain.69 
In addition, some sixty-three percent of chronic pain patients are 
unable to engage in the typical day-to-day activities that many healthy 
individuals take for granted.70 The chronic pain sufferer is significantly 
limited in his or her ability to carry out simple tasks like bathing, 
dressing, eating, cooking, shopping, and doing the laundry.71 According 
 
64. Dennis Thompson Jr., Managing Chronic Pain at Work, EVERYDAY 
HEALTH (Mar. 4, 2010), https://www.everydayhealth.com/pain-
management/managing-chronic-pain-at-work.aspx. 
65. Reddy, supra note 31, at 431. 
66. Weinman, supra note 39, at 505. 
67. WILLIAM SHAW ET AL., IMPROVING PAIN MANAGEMENT AND SUPPORT FOR 
WORKERS WITH MUSCULOSKELETAL DISORDERS: POLICIES TO PREVENT 
WORK DISABILITY AND JOB LOSS 3-7 (2017). 
68. Chronic Pain Has A Major Impact In The Workplace, C&S PATIENT 
EDUC. FOUND. (Apr. 10, 2006), https://www.conquerchiari.org/ 
articles/pain-and-depression/effects-of/chronic-pain-has-a-major-impact-
in-the-workplace.html. 
69. Philip Kinghorn et al., Developing a Capability-Based Questionnaire for 
Assessing Well-Being in Patients with Chronic Pain, 120 SOC. INDICATORS 
RES. 897, 905, 911 (2015); see Kathleen Sutherland, When Chronic Pain 
Made Me Unable to Sit, MIGHTY (Sept. 7, 2017), 
https://themighty.com/2017/09/difficulties-sitting-chronic-pain-
fibromyalgia/. 
70. Weinman, supra note 39, at 505. 
71. Paige Wyant, 16 Everyday Tasks, and What They Feel Like for a Person 
With Chronic Pain, MIGHTY (Nov. 1, 2018), https://themighty.com/ 
2018/11/doing-basic-everyday-tasks-with-chronic-pain/#conversation. 
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to studies, the inability to engage in daily living activities often leads 
to increased frustration and depression.72 
However, when a patient’s chronic pain managed and treated to 
the fullest extent, he or she suffers less and can engage in average daily 
activities, thereby experiencing greater quality of life.73 Unfortunately, 
instead of ensuring that prescription opioids are accessible for those who 
need them and inaccessible to those who do not, restrictive prescribing 
legislation has hindered access to necessary treatments. 
2. Further Exacerbating Undertreatment – The Effects of the Opioid 
Epidemic on the Chronic Pain Population 
Despite potentially disastrous consequences, legislative and judicial 
responses to the opioid epidemic have exacerbated the undertreatment 
of chronic pain. The government’s “war on drugs” has instilled fear in 
physicians which in turn has had a detrimental impact on the care they 
provide to those suffering from chronic pain.74 There are now two more 
barriers to accessing prescription opioids: (1) opiophobia; and (2) fear 
of regulatory scrutiny. 
a. Infecting Prescribers With Opiophobia75 
The first access barrier arises out of the fear that prescribing opioids 
for long periods of time “creat[es] drug addicts.”76 Health care providers 
have been infected with opiophobia.77 They fear that the use of narcotics 
 
72. Chronic Pain and Depression, AM. CHIROPRACTIC ASS’N, 
https://www.acatoday.org/Patients/Health-Wellness-Information/ 
Chronic-Pain-and-Depression (last visited Feb. 2, 2018); Rachel Noble 
Benner, Chronic Pain Not Only Hurts, It Also Causes Isolation and 
Depression. But There’s Hope, WASH. POST (Jan. 12, 2015), 
https://www.washingtonpost.com/national/health-science/chronic-pain-
not-only-hurts-it-also-causes-isolation-and-depression-but-theres-
hope/2015/01/12/db576178. 
73. Reddy, supra note 31, at 432. 
74. See Oken, supra note 5, at 1940. 
75. “Opiophobia refers to a phenomenon in which exaggerated concern about 
the risks associated with opioids prevent appropriate medical use of opioid 
analgesics. Anyone involved in the drug distribution system, as well as 
patients, family members, and members of the public, can have these 
exaggerated concerns.” Glossary – Opiophobia, PAIN & POL’Y STUDIES 
GRP., http://www.painpolicy.wisc.edu/glossary/opiophobia (last visited 
Apr. 10, 2019). 
76. See Reddy, supra note 31, at 428. 
77. See generally Dilcher, supra note 4, at 113-15. 
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causes drug abuse and addiction, and are therefore reluctant to 
prescribe, administer, or dispense controlled substances.78 
Because chronic pain is typically treated with a long-term 
prescription opioid regimen, a patient may build up tolerance and 
physiological dependence and eventually need higher doses in order to 
achieve adequate pain relief.79 Fear of “creating addicts” arises out of 
the misperception that physical dependence is equivalent to addiction.80 
But, it is important to realize that physiological dependence does not 
always indicate addiction. Though addiction may occur as a result of 
opioid pain treatment, physiological dependence and tolerance “is a 
wholly distinct and separate phenomenon.”81 Physiological dependence 
is defined as “the ability to use greatly increased amounts of a substance 
with diminished intoxicating effect.”82 On the other hand, “[a]ddiction 
is a behavioral disorder characterized by craving, drug use, and 
continued use despite personal harm.”83 The behavioral patterns of an 
addict tend to differ from that of an individual who is physiologically 
dependent and the patterns of an addict can therefore be identified. 
Those patterns include: (1) doctor-shopping; (2) repeated emergency 
room visits wherein the individual requests opioid pain relievers; (3) 
self-medicating by increasing the number of prescription medications 
used; and (4) continually using a substance despite a decreased quality 
of life.84 
A chronic pain patient may exhibit the behavioral tendencies of an 
addict if the patient is driven by untreated pain to display certain drug-
seeking behaviors.85 These individuals have been dubbed 
“pseudoaddicts” but are actually chronic pain patients who have been 
mistakenly diagnosed as addicts due to their behaviors.86 Regardless of 
similar behaviors, pseudoaddicts are distinguishable from addicts 
because they act only as a result of uncontrolled pain.87 To point out 
the difference between the two: if an addict is given the drug that he 
seeks, it only exacerbates his disease; but, if a pseudoaddict is given the  
78. Id. at 114. 
79. Reddy, supra note 31, at 436. 
80. Dilcher, supra note 4, at 115. 
81. Reddy, supra note 31, at 436.  
82. Id. 
83. Id. at 435. 
84. Id. 
85. Id. at 436. 
86. “Pseudoaddict” was coined in the late 1980s and carried through into the 
1990s when the opioid epidemic began to take hold. See id. at 435-36. 
87. See id. at 437. 
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medication he seeks, his physical functioning improves, he stabilizes, 
and the behaviors that lead to him being categorized as a 
“pseudoaddict” subside.88 
Because referring to those with physiological dependence as addicts 
stigmatizes patients, fuels opiophobia, and results in continued 
undertreatment of chronic pain patients, it is important that when 
passing future legislation, legislators are careful to differentiate between 
the two in order to reduce the fear felt by providers. 
b. To Prescribe or Not to Prescribe – Intimidating Physicians Through 
Threats of Regulatory Scrutiny 
The second barrier to access is a direct result of restrictive drug 
policies set forth by the legislatures: prescribers’ fear of regulatory 
scrutiny.89 Physicians are faced with uncertainty about what constitutes 
legitimate opioid prescribing practices and are further intimidated by a 
regulatory system riddled with the threat of sanctions.90 The risk of 
sanctions looms over physicians when deciding whether or not to write 
an opioid prescription. Prescribers may face criminal prosecution, loss 
of hospital privileges, and disciplinary action by medical licensing 
boards.91 So, a prescriber, when asked why he or she is reluctant to 
prescribe opioids to chronic pain patients, will likely respond that he or 
she fears discipline for doing so.92 In fact, forty percent of the physician 
members of the American Pain Society said just that when asked why 
they avoided prescribing opioids for chronic pain. They stated “that 
concerns about regulatory scrutiny, rather than medical considerations” 
influenced their decision.93 In response to the increase in arrests, 
prosecutions, and sanctions, doctors are changing their prescribing 
practices to avoid attracting the unwarranted attention of state medical 
boards.94 Physicians are now reducing the number of opioids prescribed 
and the dosage provided, the number of refills available to patients, and 
choosing drugs with a decreased potential for abuse.95 For example, a 
2003 study concluded that the fear of addiction and side effects limited  
88. See id. 
89. See Weinman, supra note 39, at 532. 
90. Kelly K. Dineen & James M. DuBois, Between a Rock and a Hard Place: 
Can Physicians Prescribe Opioids to Treat Pain Adequately While 
Avoiding Legal Sanction? 42 AM. J.L. & MED. 7, 8 (2016); Durning, supra 
note 11, at 215-16. 
91. Dineen & DuBois, supra note 90 at 7, 8. 
92. Weinman, supra note 39, at 532. 
93. Dilcher, supra note 4, at 85. 
94. Reddy, supra note 31, at 439. 
95. Id. 
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prescribers’ usage of opioids to treat chronic pain. Specifically, the 
study found that around half of the subjects had changed physicians at 
least once because their doctor was unwilling to treat their chronic pain 
with opioids.96 These self-protective measures may continue to further 
negatively impact the treatment of chronic pain patients.97 
Due to the already limited number of physicians willing to treat the 
chronic pain population, increases in the arrests and prosecutions of 
doctors have made it extremely difficult or nearly impossible for these 
patients to seek care.98 The strict legislative approach taken in recent 
years has instilled fear in prescribers who have since changed their 
prescribing practices and reduced and/or eliminated the benefits that 
chronic pain patients receive from opioid therapy.99 Reducing the 
benefits provided to chronic pain patients by opioid medications is an 
unsound approach to guarding against the conduct of those who wish 
to use the medications illegally.100 Though the government needed to 
act to combat the opioid epidemic, its solution was not as effective as 
it could have been. It is time that the legislators focus on providing 
access to those who are in need and restricting access to those who are 
not. To narrow that focus and create tailored legislation, it is important 
that legislators inform themselves about the basic building blocks of 
medical decision-making: physician discretion and patient autonomy. 
C. Rights to Be Restored – Physician Discretion and Patient 
Autonomy 
The basis of medical decision-making rests in the patient-physician 
relationship. That relationship is “one of mutual obligation,” which 
means that a patient’s “autonomy must be balanced with respect for 
 
96. The study was conducted by the American Pain Society, the American 
Academy of Pain, and Janssen Pharmaceutical. The study was conducted 
by Roper Starch Worldwide. The sample was made up of 500,000 
households which were representative of all households in the U.S., a total 
of 35,000 screening questionnaires were sent to a random cross-section of 
705 individuals. See Alexander DeLuca, The War on Drugs, the War on 
Doctors, and the Pain Crisis in America – Eight Years of Naked 
Emperors, DR. DELUCA (June 14, 2011), http://doctordeluca.com/ 
Library/WOD/WOD-PCA060404cWeb.htm. 
97. Dilcher, supra note 4, at 85; see Durning, supra note 11, at 217.  
98. Diane E. Hoffmann, Physicians Who Break the Law, 53 ST. LOUIS U. L.J. 
1049, 1077 (2009). 
99. Durning, supra note 11, at 216-17. 
100. Id. at 203-04. 
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the physician’s autonomy.”101 Physician discretion is the right to 
“discretionary latitude in clinical decisions.”102 Because society demands 
that the physician make his knowledge available, society provides the 
physician with sufficient discretionary latitude that allows him to 
capably and safely apply that knowledge.103 Without this freedom, the 
physician could not personalize individual care nor could he fulfill his 
obligation to use his knowledge to benefit the patient.104 
Despite the need for balance, patient autonomy dominates medical 
decision-making in the United States.105 Patients have the right and 
ability to make their own choices and decisions about medical care and 
treatment they receive, however this right is not unrestricted. Once a 
doctor provides a patient with a litany of treatment options, the patient 
is free to make decisions about the treatment plan he or she would like 
to pursue.106 
Though there is widespread recognition for patient autonomy alone, 
the patient-physician relationship cannot function without a healthy 
respect for both patient autonomy and physician discretion.107 
Unfortunately, laws surrounding opioid prescribing practices have 
diminished physician discretion and patient autonomy by dictating 
both the number of and how often opioids can be prescribed to a certain 
individual and by imposing ever harsher sanctions on physicians who 
break these new laws thereby causing them to fear prescribing opioids 
at all. Though it is recognized that opioid prescribing practices need to 
be regulated for safety purposes, a proper balance must be struck so as 
to restore physician discretion and patient autonomy.108 
II. The What and Why of Prescription Drug 
Monitoring Programs 
Legislative campaigns from the past twenty years have aimed at 
combatting the opioid epidemic have been geared towards a closed- 
101. Edmund D. Pellegrino, Patient and Physician Autonomy: Conflicting 
Rights and Obligations in the Physician-Patient Relationship, 10 J. 
CONTEMP. HEALTH L. & POL’Y 47, 51 (1994). 
102. Id. at 61. 
103. Id. at 52-53. 
104. Id. at 61. 
105. Right to Autonomy and Self Determination, USLEGAL, 
https://healthcare.uslegal.com/patient-rights/right-to-autonomy-and-
self- determination/ (last visited Mar. 8, 2019). 
106. Id. 
107. Pellegrino, supra note 101, at 57. 
108. See Oken, supra note 5, at 1943. 
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regulation system with a “‘zero-tolerance’ approach.”109 These new laws 
are jam-packed with burdensome administrative processes, ever-harsher 
penalties, and more militant and expensive enforcement tactics.110 The 
rigid nature of recent legislative enactments has placed a heavy burden 
on both patients and prescribers.111 For example, strict limits on the 
number of pills that can be dispensed at one time and limits on the 
amount of time a patient is permitted to receive a specific medication 
creates substantial obstacles for patients in remote areas or those who 
have a disabling condition and cannot travel to collect their 
prescriptions.112 Furthermore, due to recent legislation, physicians are 
more reluctant than ever to prescribe opioids, not only because they 
dread the trek through the newly created administrative maze, but also 
because they fear prosecution for making a good faith mistake.113 The 
new system will continue to limit patient access to prescription opioids 
unless physicians feel comfortable prescribing and access is permitted, 
encouraged, and facilitated by the government.114 It is clear that there 
needs to be a balance between: (1) the freedom of physicians to use 
their judgment in prescribing; (2) efficient processes by which 
individuals in need of medication can receive it; and (3) legitimate law 
enforcement efforts.115 Though the balance has yet to be struck, many 
state governments took a step in the right direction by creating and 
implementing prescription drug monitoring programs. 
A. What is a Prescription Drug Monitoring Program? 
PDMPs are defined and function as “statewide electronic 
database[s] which collect[] designated data on substances dispensed in 
 
109. See Anderson & Davis, supra note 3, at 341; see also Oken, supra note 5, 
at 1942. 
110. Oken, supra note 5, at 1942; see also Anderson & Davis, supra note 3, at 
340-41. 
111. Oken, supra note 5, at 1942-43; see e.g., Anderson & Davis, supra note 3, 
at 340-41. 
112. See e.g., ALASKA STAT. § 08.36.355 (2019); H.B. 333, 2017 Gen. Assemb., 
Reg. Sess. (Ky. 2017); N.J. ADMIN. CODE § 13:45H-7.5-7.20 (2019); Act 
122, 2016 Gen. Assemb., Reg. Sess. (Pa. 2016); Act 125, 2016 Gen. 
Assemb., Reg. Sess. (Pa. 2016); Anderson & Davis, supra note 3, at 358. 
113. Anderson & Davis, supra note 3, at 359. 
114. Id. 
115. See generally Oken, supra note 5, at 1942-43; See also Jeffrey A. Singer, 
In the Opioid Crisis, Keep Your Eyes On Heroin and Fentanyl, CATO 
INST., (Oct. 25, 2017), https://www.cato.org/publications/commentary/ 
opioid-crisis-keep-eyes-heroin-fentanyl. 
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the state.”116 These programs contain and compile information on 
controlled substance prescriptions written by prescribers and dispensed 
by pharmacies.117 PDMPs collect data via prescribers and pharmacists 
entering controlled substance prescriptions into the centralized 
database thereby making the information available to authorized 
users.118 Authorized users typically include prescribers and pharmacists, 
as well as licensure boards, law enforcement, medical examiners, drug 
courts, criminal diversion programs, addiction treatment programs, 
insurance companies, and other public health and safety agencies.119 
The extent of access varies among users, but it is clear that only 
authorized users can access the data and those users can only access 
the data with login credentials provided by registering with the 
requisite state prescription drug monitoring program.120 Once 
authorized, users can see data including the name of the patient, 
prescriber, pharmacy, prescription, dose, and form of payment.121 
Armed with the information contained in the PDMP interface, 
authorized users can use PDMP data to improve patient safety by 
allowing prescribers to: (1) identify patients who are obtaining opioids 
from multiple providers; (2) calculate the total amount of opioids 
prescribed per patient per day; and (3) identify patients who are 
prescribed substances that may increase the risk of abuse.122 Moreover, 
the information collected by PDMPs may also be used to facilitate 
access to prescription opioids for those in need; identify and prevent 
drug abuse and diversion; and aid in identifying drug-addicted 
individuals, thereby enabling intervention and treatment.123 
 
116. State Prescription Drug Monitoring Programs – Questions and Answers, 
U.S. DEP’T OF JUSTICE & DRUG ENF’T AGENCY, 
https://www.deadiversion.usdoj.gov/faq/rx_monitor.htm#4 (last 
updated June 2016). 
117. Finklea et al., supra note 29; What States Need to Know About PDMPs, 
CTR. DISEASE CONTROL & PREVENTION, https://www.cdc.gov/ 
drugoverdose/pdmp/states.html (last visited Nov. 11, 2017). 
118. See CDC Fifty-State Survey, supra note 18. 
119. Steer & Gass, supra note 16, at 7. 
120. Rebecca L. Haffajee, Preventing Opioid Misuse with Prescription Drug 
Monitoring Programs: A Framework for Evaluating the Success of State 
Public Health Laws, 67 HASTINGS L.J. 1621, 1634 (2016). 
121. Steer & Gass, supra note 16, at 6-8. 
122. See LISA N. SACCO ET AL., PRESCRIPTION DRUG MONITORING PROGRAMS, 
CONGRESSIONAL RES. SERV. 4 (2018); Austin Frakt, A Helpful Tool to 
Combat the Opioid Crisis, N.Y. TIMES (Sept. 11, 2017), 
https://www.nytimes.com/2017/09/11/upshot/a-helpful-tool-to-combat-
the-opioid-crisis.html; Haffajee, supra note 120, at 1634-35. 
123. SACCO ET AL., supra note 122, at 3. 
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A majority of states have operational PDMPs.124 As of recently, 
legislation authorizing the collection of data is in place in every state 
except Missouri.125 Despite the widespread creation and implementation 
of PDMPS, each program varies in several important ways. First, state 
PDMPs tend to differ with respect to the agency responsible for housing 
and maintaining them.126 The agency charged with managing the 
PDMP may be located in either the state’s Board of Pharmacy, 
Department of Health and Human Services, or a law enforcement 
agency.127 Second, states tend to take different stances on which 
conditions need to be met in order for a user to be authorized to request 
and receive PDMP reports.128 Lastly, though some states merely suggest 
the use of PDMPS, other states mandate their use. For example, a state 
may require prescribers to check the PDMP before writing a 
prescription for an opioid.129 Overall, even though PDMPs vary widely 
across the forty-nine states that have them, the principal goal of 
effectively regulating controlled substances is generally accepted and 
championed by each one.130 
 
124. See Steer & Gass, supra note 16, at 5. 
125. Id. at 7; Missouri does not have a functioning PDMP due to consistent 
filibustering when legislation is introduced. Senator Rob Schaaf 
consistently leads filibusters against any PDMP brought in front of the 
Missouri legislature. Megan Thielking, Missouri is the Only State Not 
Monitoring Prescription Drug Use. Will It Finally Create a Database?, 
STAT NEWS (Mar. 7, 2017), https://www.statnews.com/2017/03/07/ 
missouri-prescription-drug- database. 
126. Blumenthal & Seervai, supra note 28; Steer & Gass, supra note 16, at 7. 
127. SACCO ET AL., supra note 122, at 4. 
128. Id.; see also Prescription-Drug Monitoring Cuts Doctor-Shopping for 
Painkillers, FOX NEWS (Feb. 17, 2017), http://www.foxnews.com/ 
health/2017/02/17/prescription-drug-monitoring-cuts-doctor-shopping-
for-painkillers.html. 
129. See FOX NEWS, supra note 130. Kentucky, New York, and Ohio are 
potential models for states looking to mandate prescriber use. See also 
Mandated Use of State Prescription Drug Monitoring Programs (PMPs) 
– Highlights of Key State Requirements, NAT’L ALLIANCE FOR MODEL 
STATE DRUG L. (June 30, 2017), http://namsdl.dynamicwebware.com/ 
News%20Tab/Highlighted%20Issues/Mandated%20Use%20of%20State%
20Prescription%20Drug%20Monitoring%20Programs%20(PMPs)%20-
%20Highlights%20of%20Key%20State%20Requirements%20(June%2030
%2C%202017).pdf. 
130. See Steer & Gass, supra note 16, at 8. 
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B. Why a Prescription Drug Monitoring Program? 
The risks presented by prescription opioids make it clear that their 
use needs to be monitored.131 But, combatting prescription opioid 
diversion and abuse is no easy feat. An effective monitoring regime 
requires the coordinated effort of various state regulatory, judicial, and 
law enforcement bodies.132 To be clear, this Note recognizes that 
PDMPs serve to supplement other state drug enforcement laws. But, 
this Note focuses on the argument that, with a few changes, PDMPs 
will address the issues surrounding prescription opioids. 
Notwithstanding the need for other state laws, a top priority should be 
that the program and accompanying guidelines enable health care 
providers to rely on their judgment and confidently provide pain 
treatments to those in need without fear of prosecution and criminal 
discipline.133 
C.  Current Regulatory and Legislative Problems 
Aside from the laws that create PDMPs, other current state policies 
restrict prescriber autonomy in three major ways.134 First, various state 
policies place limitations on the ability to prescribe opioid pain 
medications by preventing prescribing to patients with certain 
characteristics. These policies focus on characteristics like age, 
diagnosis, or prognosis.135 These restrictions tend to diminish a 
prescriber’s ability to provide treatment to those in need and hinder 
patient access to much needed pain treatment.136 For example, if a 
physician treats a patient who under state law cannot receive an opioid 
prescription for their pain, that physician is forced to seek out another 
potentially less effective treatment method. Second, certain states 
require prescribers to consult with at least one other provider before 
writing a prescription for an opioid.137 Requiring a physician to present 
his or her recommendations to another in order to write a prescription 
deprives the doctor of his discretion and makes it more difficult for  
131. Prescription opioids tend to be safe when taken as directed, but because 
the drug interacts with pain receptors in the brain and nervous system 
and produces a sense of euphoria in addition to pain relief, they can be 
misused and abused. See generally COMMONWEALTH OF PA. & THE PA. 
PHARMACISTS ASS’N, supra note 9; see also Steer & Gass, supra note 16. 
132. Durning, supra note 11, at 241. 
133. Id. at 215-16. 
134. Dilcher, supra note 4, at 101-02. 
135. Id. at 103.  
136. Id.; see also Oken, supra note 5, at 1938-39; Trehan, supra note 4, at 
962. 
137. See Dilcher, supra note 4, at 103-04. 
Health Matrix·Volume 29·Issue 1·2019 
50 Shades of Data Sharing:  How a Uniform Fifty-State Prescription Drug 
Monitoring Program Can Restore Discretion to Opioid Prescribers and 
Autonomy to Chronic Pain Patients 
484 
chronic pain patients to receive the opioid pain medications they 
need.138 Last, but most importantly, though federal law does not limit 
the quantity of drugs that a prescriber can dispense, states are 
beginning to limit the amount of opioid painkillers that can be 
dispensed or prescribed at one time.139 States claim they are trying to 
control the availability of prescription opioids that present a potential 
for abuse and diversion, but state lawmakers need to understand the 
real-life implications of their policies – hindering patient access to 
needed pain relief treatment.140 For a chronic pain patient with a 
disabling medical condition that renders it difficult for him to return to 
the doctor multiple times to receive a new prescription and to travel to 
a pharmacy to fill that prescription, may have to go days without 
necessary medication.141 Patients without reliable transportation or 
those who live in rural areas and have to travel long distances may 
suffer the same fate.142 
Opioids are safe and effective in the treatment and management of 
pain but for them to be effective, they must be accessible.143 There needs 
to be a substantially greater focus on palliative care when creating a 
balanced policy approach relating to prescription opioids.144 Policies and 
programs aimed at monitoring prescription opioids should crackdown 
on unintended third parties and not on the intended recipients of 
prescription opioids. Any response to the prescription opioid epidemic 
that prevents patient access to medication and restricts prescribers’ 
abilities to manage pain could inappropriately further contribute to the 
already rampant public health crisis of pain undertreatment.145 PDMPs 
do the opposite; they assist prescribers and pharmacists in identifying 
illict behavior while also ensuring that patients have access to the 
medications they need. 
D. The Benefits of PDMPs 
Overall, PDMPs are taking promising steps to mitigate the opioid 
epidemic.146 These data-collection programs continue to be among the 
 
138. See id. 
139. See id. at 100. 
140. See Weinman, supra note 39, at 539; Dilcher, supra note 4, at 104-05. 
141. Dilcher, supra note 4, at 105. 
142. Id. at 104-05. 
143. Id. at 82. 
144. Id. at 109; Durning, supra note 11, at 239-40. 
145. See Durning, supra note 11, at 241; see also Weinman, supra note 39, at 
539. 
146. See, e.g., Frakt, supra note 122, SACCO ET AL., supra note 122. 
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most promising interventions aimed at combatting drug abuse and 
diversion while ensuring that those in need of prescription opioid 
painkillers have access.147 PDMPs allow prescribers and pharmacists to 
identify, prevent, and deter drug abuse and diversion practices.148 When 
a physician or other authorized user checks the database and sees an 
unusual pattern of opioid distribution, they can deny or change a 
prescription, screen for an opioid/substance abuse disorder, or even 
counsel the patient and suggest seeking other forms of pain 
management or addiction treatment if necessary.149 
In 2012, a review article concluded that PDMPs, in general, are 
responsible for reducing doctor-shopping150 and prescription drug 
abuse.151 Statistics specifically show that in states with active PDMPs, 
when investigating cases of doctor shopping, law enforcement officers 
were able to solve cases significantly faster than in states without; and 
while opioid abuse rates were increasing, the increase was slower in 
states with PDMPs.152 Recent research funded by the National Institute 
on Drug Abuse arrived at the same conclusion – PDMPs are effective 
in reducing drug abuse, misuse, and curbing overdose deaths.153 After 
reviewing the relevant statistics, researchers concluded that state 
 
147. See, e.g., Frakt, supra note 122, SACCO ET AL., supra note 122; State 
Successes, CTR. FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/drugoverdose/policy/successes.html (last visited 
Nov. 11, 2017). 
148. SACCO ET AL., supra note 122. 
149. Frakt, supra note 122. 
150. Doctor shopping occurs when a patient visits multiple providers to get 
multiple prescriptions from each of them without the providers knowing 
about the other prescriptions. Doctor Shopping Laws, CTR. FOR DISEASE 
CONTROL& PREVENTION (2012), https://www.cdc.gov/phlp/docs/menu-
shoppinglaws.pdf. 
151. SACCO ET AL., supra note 122. 
152. Id. 
153. Overall, if a state implements a PDMP, there is likely to be a decrease of 
1.12 opioid-related overdose deaths per 100,000 people annually. See 
Prescription Drug Monitoring Programs Linked to Reductions in Opioid 
Overdose Deaths, NAT’L INST. ON DRUG ABUSE (June 22, 2016), 
https://www.drugabuse.gov/news-events/news-
releases/2016/06/prescription-drug-monitoring-programs-linked-to-
reductions-in-opioid-overdose-deaths. 
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implementation of PDMPs was associated with an overall reduction in 
opioid-related overdose deaths.154 
By providing physicians with a medium through which they can 
efficiently monitor a patient’s opioid use, while also paving the way for 
physicians to safely continue to prescribe opioids, PDMPs have worked 
to not only restore decisional autonomy to prescribers and ensure 
efficacious access to prescription opioids for chronic pain patients, but 
they have also taken steps that have proven successful in combatting 
the opioid epidemic. PDMPs have finally struck the policy balance that 
prescribers, patients, and lawmakers have been waiting for. 
Unfortunately, despite the overarching success of PDMPs, the lack of 
uniformity amongst the programs has led to problems that can only be 
fixed by instating a uniform fifty-state PDMP. The uniform PDMP will 
combat the challenges facing existing PDMPs by implementing new 
strategies that result in greater collection and effective utilization of 
data; greater interstate data sharing; and fewer unintended 
consequences impacting access. 
III. Problems Within Prescription Drug Monitoring 
Programs and Their Solutions 
A. Problems with Current PDMPs 
The significant differences among state PDMPs demonstrate the 
lack of interstate communication and organization that unfortunately 
surrounds many of the attempts to combat the opioid epidemic.155 
Despite the fact that all forty-nine states with operational PDMPs 
share many of the same goals, all forty-nine programs vary.156 The 
 
154. The NIDA-funded research study found that state implemented PDMPs 
that monitored greater numbers of drugs with high potential for abuse 
and took care to more frequently update data had a larger decrease in 
opioid-related overdose deaths than PDMPs that did not. Specifically, 
states “that monitored four or more drug schedules and updated their 
information at least weekly” had “1.55 fewer opioid-related overdose 
deaths per 100,000” annually than other programs. See id. 
155. See Haffajee, supra note 120, at 1625. 
156. Prescription drug monitoring programs vary widely in ways such as: who 
can see the data; whether unsolicited reports are sent to users; whether 
prescribers/dispensers can delegate access to a certain person; whether a 
patient has to be notified when and if their data is accessed; if data is 
shared with other states; how frequently data is updated; and whether 
training is required in order to become an authorized user. See Haffajee, 
supra note 120, at 1636; SACCO ET AL., supra note 122; Prescription Drug 
Monitoring Frequently Asked Questions (FAQ), PDMP ASSIST, 
http://www.pdmpassist.org/content/prescription-drug-monitoring-
frequently-asked-questions-faq (last visited Apr. 9, 2019). 
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variations amongst the programs have led to four key issues that must 
be addressed in order for PDMPs to continually succeed.157 These issues 
are: (1) failure to collect sufficient data; (2) failure to effectively use 
collected data; (3) failure to distribute data across state lines; and (4) 
consequences of improperly structured PDMPs. 
1. Failure to Collect Sufficient Data 
First, PDMPs, unfortunately, fail to collect enough data 
successfully combat the opioid epidemic. Many state PDMPs do not 
require prescribers or pharmacists to report vital information that could 
assist in tracking down doctor-shoppers or those who engage in 
prescription opioid diversion. For example, to evade detection, drug 
abusers, doctor-shoppers, and prescription opioid diverters often pay 
for prescription pain killers in cash rather than using their insurance 
plan.158 It is important for states to track the method of payment used 
by an individual picking up a prescription. Though there is an inherent 
risk in failing to track cash transactions,159 a large percentage of states 
do not require pharmacists to record the payment method that the 
patient uses when picking up a prescription opioid.160 Most state 
PDMPs also do not require pharmacists to record the name or identity 
of the individual picking up the prescription opioid.161 In failing to 
record the identity of the individual, these policies create a risk for 
diversion. Lastly, as of 2014, state PDMPs failed to collect all relevant 
prescriber data.162 State PDMPs fail to collect data relating to the 
disciplinary history or whether a prescriber is even alive. 163 The lack of 
data collection could allow a drug-seeking individual to fill an opioid 
prescription: (1) written by a prescriber who is no longer permitted to 
write prescriptions; or (2) written by an individual other than the 
deceased prescriber on a deceased prescriber’s prescription pad. Fixing 
this data gap would enable PDMPs to continue to allow access to those 
in need of opioids while better serving the goal to prevent unintended 
access. 
 
157. See Hafaajee, supra note 120, at 1637, 1676. 
158. Joanna Shepherd, Combating the Prescription Painkiller Epidemic: A 
National Prescription Drug Reporting Program, 40 AM. J.L & MED. 85, 
86 (2014). 
159. To evade detection, drug abusers, doctor-shoppers, and prescription 
opioid diverters often pay for prescription pain killers in cash rather than 
using their insurance plan. Id. 
160. Id. at 105. 
161. Id. 
162. Id. at 106. 
163. Id. 
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2. Failure to Effectively Use the Data that is Collected 
Authorized users with access to state PDMPs fail to properly enter 
or use data that is collected. Specifically, many prescribers worry that 
entering data into or checking the PDMP will prove to be burdensome 
and become another task to complete in order to meet the requisite 
“duty of care.” Prescribers fear that if this newly enhanced duty were 
to be unmet, they would be subjected to sanctions and lawsuits.164 
Though some states have tried to scare prescribers into using 
prescription drug monitoring programs by threatening disciplinary 
action for non-use, there is no universal “carrot and stick” approach 
that has successfully raised the prescriber participation rate.165 
As a result, at least eleven states are now requiring that prescribers 
check PDMPs when writing a prescription for opioids for certain 
patients and under particular circumstances.166 For example, a newly 
enacted Pennsylvania law requires a prescriber to query the PDMP 
system each time a patient is prescribed an opioid but does not require 
a query if a patient is admitted to a licensed healthcare facility. Yet, 
most states do not require prescribers and pharmacists to consult 
PDMP data at all.167 However, suppose that a prescriber, regardless of 
whether he is required to do so, does consult a PDMP. Often a new 
issue arises – a failure to report timely data.168 Because prescribers and 
pharmacists may only input data once every week or two, other 
authorized users cannot see the most up-to-date or timely data. If a 
prescriber or pharmacist does not have access to the most recent data, 
they may be unaware of new information that indicates potential drug 
abuse or doctor-shopping.169 
3. Failure to Distribute the Data Collected Across State Lines 
Third, although a significant number of PDMPs are making efforts 
to share data with other states, there are gaps in the uniformity, 
efficacy, and real-time sharing of data across state lines.170 
 
164. See id. 
165. See id. at 86. 
166. Haffajee, supra note 120, at 1636 n.86. 
167. Kelly K. Dineen, Addressing Prescription Opioid Abuse Concerns in 
Context: Synchronizing Policy Solutions to Multiple Complex Public 
Health Problems, 40 L. & PSYCHOL. REV. 1, 61 (2016). 
168. Id. at 62. 
169. See What States Need to Know About PDMPs, CTR. FOR DISEASE 
CONTROL & PREVENTION (Oct. 3, 2017), https://www.cdc.gov/ 
drugoverdose/pdmp/states.html. 
170. Shepherd, supra note 158, at 107. 
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Implementing full interstate data-sharing measures will involve making 
extensive changes to existing programs and require coordination among 
many regulatory and legislative bodies, which is a major challenge for 
new data-sharing initiatives.171 Unfortunately, some states have not 
enacted legislation that provides the authority to share this type of 
data.172 The federal government tried to jumpstart interstate data 
sharing by creating the Prescription Monitoring Information Exchange 
(“PMIX”). PMIX is a system intended to promote and enable 
interoperability between state PDMPs.173 The system provides 
information on an individual’s prescription drug history by establishing 
RxCheck Hubs.174 Hubs can exist at either the national or state level 
and information can be shared amongst all hubs.175 For privacy 
purposes, patient data is encrypted as it passes through the hubs and 
no data is actually stored on the hub.176 But instead of joining PMIX, 
forty-one states became members of PMP InterConnect which 
facilitates the transfer of PDMP data between participating states.177 
Though this is a step in the right direction, eight states still fail to share 
their data with the rest of the country which may provide an incentive 
for drug abusers and diverters to cross state lines to obtain prescription 
opioids. 
4. The Consequence of Improperly Structured PDMPs 
Lastly, if improperly tailored or structured, PDMPs may have an 
unintended consequence.178 Though PDMPs typically strike the proper 
balance between physician discretion, patient access, and efforts to 
combat the opioid epidemic, prescribers may still refuse or hesitate to 
prescribe opioids that are monitored by the PDMP due to the extra 
 
171. Id. 
172. Id. 
173. Prescription Monitoring Information Exchange (PMIX) Architecture, 
PRESCRIPTION DRUG MONITORING PROGRAM TRAINING & TECHNICAL 
ASSISTANCE CTR., http://pdmpassist.org/content/prescription-drug-
monitoring-information-architecture-pmix (last visited Mar. 16, 2018). 
174. Id. 
175. Id. 
176. PMIX National Architecture Overview, PRESCRIPTION DRUG MONITORING 
PROGRAM TRAINING & TECHNICAL ASSISTANCE CTR., 
https://www.pdmpassist.org/pdf/PMIX%20National%20Architecture%2
0Overview.pdf (last visited Feb. 17, 2019). 
177. NABP PMP InterConnect: The Only National Network of State-Based 
PMPs, NAT’L ASS’N BOARDS PHARMACY, https://nabp.pharmacy/ 
initiatives/pmp-interconnect/ (last visited Jan. 9, 2019). 
178. SACCO ET AL., supra note 122. 
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scrutiny by law enforcement.179 These increasing concerns may further 
contribute to the crisis of undertreatment that PDMPs were designed 
to alleviate. In addition, some patients may also fear scrutiny from law 
enforcement authorities for using prescription opioids monitored by the 
PDMP, even if they have a legitimate medical reason for doing so.180 
B. How a Uniform Approach Can Fix the Problems that Exist Within 
Current State PDMPs 
Many of the problems that relate to PDMPs arise out of a lack of 
regulatory and legislative uniformity. The best way to address 
contemporary challenges is to give states the option to adopt a new, 
comprehensive, and uniform PDMP laws that quell patient and 
prescriber concerns by restoring autonomy to both parties while also 
bringing down the “legislative hammer” on those who contribute to the 
opioid epidemic. 
1. State Licensing Boards, New Reporting Requirements, and the 
Solution to Inadequate Data Collection 
To improve data collection, the uniform PDMP will require that 
prescribers and pharmacists include more information in the reports 
they submit. Though entering more information into the PDMP 
interface may place a burden on prescribers and pharmacists, increasing 
the amount of available information will assist them in identifying 
doctor-shoppers and individuals who divert prescription opioids.181 
As it pertains to prescribers, the uniform PDMP will adopt the 
information reporting requirements of Indiana’s PDMP, INSPECT.182 
The uniform PDMP, like INSPECT, will require that, whenever a 
controlled substance is prescribed, the prescriber reports: (1) the 
recipient’s name and date of birth; (2) the national drug code number;183 
(3) the date the prescription was written; (4) the quantity and number 
of days of supply of the opioid given; (5) the prescriber’s Drug 
Enforcement Administration (DEA) registration number; and (6) 
whether the prescriber transmitted the prescription to the pharmacy 
orally or in writing.184 
 
179. Id. 
180. Id. 
181. See Shepherd, supra note 158, at 106, 108. 
182. See generally IND. CODE § 35-48-7 (2017) (repealed and amended by 2010 
Ind. Leg. Serv. 84 (West)). 
183. National Drug Code Directory, FOOD & DRUG ADMIN., 
https://www.fda.gov/drugs/informationondrugs/ucm142438.htm (last 
visited Feb. 9, 2019). 
184. IND. CODE § 35-48-7-8.1 (2018).  
Health Matrix·Volume 29·Issue 1·2019 
50 Shades of Data Sharing:  How a Uniform Fifty-State Prescription Drug 
Monitoring Program Can Restore Discretion to Opioid Prescribers and 
Autonomy to Chronic Pain Patients 
491 
As it pertains to pharmacists, the uniform PDMP will adopt the 
reporting requirements currently used by the Washington and Alabama 
PDMPs.185 Before an opioid is dispensed, the uniform PDMP will 
require pharmacists to report: (1) patient identifiers including their 
name, social security number, and date of birth; (2) the name of the 
drug dispensed; (3) the date the drug is dispensed; (4) the quantity of 
the drug dispensed; (5) the prescriber’s name; (6) the dispenser’s name 
and location;186 and (7) the method of payment used.187 Adopting these 
reporting requirements resolves an issue that surrounds current PDMPs 
– specifically, the failure to record the identity and method of payment 
used by the individual picking up the prescription. Requiring the 
pharmacist to record a patient identifier and the method of payment 
will decrease possible opportunities for diversion and assist in 
identifying individuals who engage in those practices. 
Adopting elements from existing PDMPs is a step in the right 
direction, but it does not completely solve the problem of inadequate 
data collection. That is why the uniform PDMP must enter uncharted 
territory and begin collecting data relating to the disciplinary or 
life/death status of prescribers.188 To facilitate this data collection, the 
uniform PDMP will be maintained by state professional licensing 
agencies. The state licensing agency in charge of the uniform PDMP 
will designate a group of people to form a board (“the Board”). State 
licensing agencies should have discretion to decide the specific duties 
that will be assigned to the Board and the qualifications Board members 
should have. However, it is recommended that the Board be charged 
with not only maintaining the PDMP, but also keeping prescriber data 
up to date. Much like the data-entry timelines that apply to 
pharmacists and prescribers, the Board should routinely update 
prescriber statuses within the database.189 However, because prescriber 
statuses are not likely to change as frequently as an individual’s 
prescription, the board should be required to check and update 
prescriber status once a month. By continually updating prescriber 
information within the database, the uniform PDMP will take 
significant steps toward preventing individuals from filling prescriptions 
for opioids that are invalid because they are written by a prescriber 
 
185. See generally WASH. REV. CODE § 70.225 (2018); see also H.B. 150, 
2013 Gen. Assemb., Reg. Sess. (Ala. 2013). 
186. Prescription Monitoring Program, WASH. REV. CODE § 70.225.020(2) 
(2018). 
187. H.B. 150, 2013 Gen. Assemb., Reg. Sess. (Ala. 2013). 
188. See Shepherd, supra note 158, at 106, 111. 
189. See 14-118-11 ME. CODE. R. § 5(C)(1) (LexisNexis 2017); OR. ADMIN. R. 
410-121-4010(1) (2019). 
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who is no longer licensed or by an individual using a deceased 
prescriber’s prescription pad.190 
2. Curing the Ineffective Utilization of PDMP Data by Facilitating 
Access, Enrollment, and Consultation 
Addressing the ineffective utilization of PDMP data is more 
difficult than addressing the issue of data collection, but it can be done 
by: (1) providing simple online access and increasing prescriber and 
pharmacist participation by increasing the availability of educational 
and promotional campaigns; (2) mandating prescriber use; (3) allowing 
prescribers to designate someone on staff to access the PDMP on their 
behalf; and (4) issuing automated reports.191 
a. Expediting Enrollment and Mandating Agency-Sponsored Training 
Programs 
First, many prescribers and pharmacists attribute their lack of 
PDMP consultation to burdensome enrollment and difficulties 
associated with use.192 For example: in some states individuals that 
register for the PDMP must also look through an extensive list of 
practices and register individually for each practice applicable to 
them.193 This process could take hours and may dissuade prescribers 
and pharmacists from registering with the PDMP. Moreover, after 
gaining access, many physicians argue that it takes a considerable 
amount of time to navigate the online portal and therefore do not use 
it.194 
To facilitate prescriber use, the uniform PDMP will first provide a 
streamlined enrollment process that will institute automatic PDMP 
registration. This automatic registration will be triggered by DEA 
controlled substance registration.195 Massachusetts has the MassPAT 
system, which automatically enrolls DEA registrants.196 Following this 
program, the uniform PDMP will issue registration to any physician, 
dentist, or podiatrist, who is duly authorized to practice in the state 
and is registered with the DEA to prescribe or dispense prescription 
 
190. See Shepherd, supra note 158, at 111. 
191. SACCO ET AL., supra note 122; see also State Prescription Drug Monitoring 
Programs– Questions and Answers, supra note 116. 
192. See Marilyn Bulloch, The Evolution of the PDMP, PHARMACY TIMES (July 
25, 2018), https://www.pharmacytimes.com/contributor/marilyn-
bulloch-pharmd-bcps/2018/07/the-evolution-of-the-pdmp. 
193. See generally 105 MASS. CODE REGS. § 700.004 (2019). 
194. SACCO ET AL., supra note 122. 
195. See 105 MASS. CODE REGS. § 700.004(D) (2019). 
196. Id. 
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opioids.197 By automatically enrolling DEA registrants, the uniform 
PDMP will shift the burden of enrollment to the state licensing agency 
that manages the uniform PDMP. 
The uniform PDMP will also require the Board to provide training 
on how to access and use PDMP data.198 First, the Board should 
contract with the vendor who provides the interface in order to obtain 
and design an online technical assistance program.199 At a minimum, 
the program should include tutorials on: how to access prescription 
monitoring information; rights of persons whose information the user is 
viewing; responsibilities of persons who access PDMP information; 
permitted uses of PDMP information; and possible penalties for failure 
to use or improper use by authorized users.200 The online system will 
then be offered to registered PDMP users.201 Authorized users must 
successfully complete the training program before having access to the 
system.202 The Board should also be responsible for engaging with the 
vendor on a regular basis to provide new tutorials as needed; keeping 
the online technical assistance program up-to-date and informing 
authorized users of the new tutorials. For example, if a new feature was 
added to the uniform PDMP, the Board should be responsible for 
contacting the vendor, specifying the new tutorial that is needed, and 
informing all of the authorized users in the state about that new 
tutorial. Once an authorized user is informed of a new tutorial, that 
user must successfully complete the tutorial within six months.203 
By expediting the enrollment process through automatic 
registration and mandated agency-sponsored training programs, 
prescribers and pharmacists will be more likely to competently comply 
with the requirements of the uniform PDMP. 
b. Mandating PDMP Consultation 
Taking steps to facilitate enrollment and use are not enough. The 
best way to ensure that prescribers and pharmacists consult the PDMP 
 
197. See id. 
198. See e.g., 105 MASS. CODE REGS. § 700.004(F)(2) (2019); N.J. STAT. ANN. 
§ 45:1-46(26)(k) (West 2018); MINN. STAT. § 152.126(2)(b) (2019). 
199. MINN. STAT. § 152.126(2)(b) (2019). 
200. See N.J. STAT. ANN. § 45:1-46(26)(k) (West 2019). 
201. See id. 
202. See 105 MASS. CODE REGS. § 700.004(F)(2) (2019). 
203. Based off the idea adopted by Massachusetts lawmakers that authorized 
users must successfully complete a training program that meets the 
specifications sets by the agency that maintains the PDMP every two 
years. See e.g., 105 MASS. CODE REGS. § 700.004(F)(2)(e) (2019). 
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is to mandate it.204 Therefore the uniform PDMP, will require that 
authorized users who dispense or prescribe opioids check the PDMP 
before doing so. The uniform PDMP will require that dispensers, health 
facilities, or individuals with DEA registration numbers both check the 
system before prescribing and enter all prescribed or dispensed opioids 
into the system. By issuing a comprehensive consultation mandate, the 
uniform PDMP will ensure that most, if not all, pharmacies, drug 
wholesalers, pharmacists, prescribers, and the like will check the 
system, thereby cutting down illicit drug practices.205 
c. Reducing the Clinical Workflow Through Delegation 
Because it is important that prescribers and pharmacists spend 
more time with their patients or customers and less time consulting the 
PDMP, in lieu of the mandate, the uniform PDMP will allow authorized 
users to delegate the responsibility of checking the uniform PDMP to 
other individuals such as RNs, LPNs, CRNAs, and pharmacy 
technicians.206 However, there will be restrictions on whether or not an 
individual can be a delegate. For example, an individual who is eligible 
in his or her own right to become an authorized user may not serve as 
a delegate under another authorized user.207 Furthermore, the 
authorized user must submit a request to the Board asking it to create 
a separate “delegate sub-account” for the authorized users.208 The Board 
will have discretion to deny the authorized user’s request and may 
thereby refuse to create a delegate sub-account. 
If the Board grants access, delegates are considered “permissible 
users” and are permitted to access the same data as authorized PDMP 
users.209 To avoid improprieties and protect patient privacy concerns, 
the uniform PDMP will set forth specific purposes for which authorized 
users and their delegates may access PDMP data. To avoid penalties, 
authorized and permissible users may only access PDMP data to the 
extent that the information relates specifically to a current patient to 
whom the prescriber is: (1) prescribing or considering prescribing a 
controlled substance; (2) providing emergency medical treatment; (3) 
 
204. White House Comm’n, supra note 25. 
205. Studies show that the rate of doctor-shopping drops in states that require 
pharmacists and prescribers to consult the PDMP prior to do dispensing 
or prescribing opioids. See Frakt, supra note 122. 
206. See e.g., H.B. 150, 2013 Gen. Assemb., Reg. Sess. (Ala. 2013); MINN. 
STAT. § 152.126 (2019); see 14-118-11 ME. CODE. R. § 7 (LexisNexis 2017); 
105 MASS. CODE REGS. § 700.004(I)(1) (2019). 
207. See 105 MASS. CODE REGS. § 700.004(I)(1) (2019). 
208. See generally 105 MASS. CODE REGS. § 700.004(I)(2) (2019). 
209. See MINN. STAT. § 152.126(5) (2019). 
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providing care to someone reasonably believed to have a substance 
abuse problem; or (4) there is a clinically valid reason for checking the 
system. 210 
Delegation will make it easier for authorized users to work PDMP 
consultation into their everyday clinical duties. Prescribers will be able 
to spend more time with patients and will be less likely to argue that 
mandated PDMP consultation constitutes a significant burden. 
d. Board Issued Reports 
To further ensure that PDMP data is utilized in the most effective 
way the Board will determine whether or not to issue a report indicating 
that there are concerns regarding a patient seeking or receiving 
opioids.211 The Board shall have discretion to determine the way by 
which patients are flagged in the system, thereby indicating that a 
report may need to be issued. For example, the Board may hire 
individuals to review entries, or more efficiently, invest in software that 
reviews each entry and alerts the Board when there is an issue. Once 
disseminated to providers and pharmacies, the report will instruct 
authorized users to log into their accounts to view the patient’s 
prescription history.212 When viewing the report, the authorized user 
will see: the names of the providers and pharmacies that prescribed or 
dispensed opioids to the patient; the name and quantity of the drug 
prescribed or dispensed; and other prescriptions that the patient was 
prescribed in the last three months.213 Though it may strike some as a 
violation of the patient’s privacy, the report is only available to 
authorized users, and not law enforcement. The report is issued to 
encourage authorized users to talk to their patients about possible 
treatment for abuse and misuse while also taking proactive steps toward 
preventing further illicit behavior. 
When considering whether to disseminate a report, the Board 
should consider whether the behavior exhibited by the patient is 
indicative of: (1) abuse, misuse, or diversion of a controlled substance; 
or (2) doctor-shopping.214 If the Board notices that an individual 
receives an excessive amount of prescriptions containing opioids,  
210. See 105 MASS. CODE REGS. § 700.004(C)(2) (2019). 
211. See e.g., N.J. STAT. ANN. § 45:1-46(26) (West 2019); see also Guidance 
on PDMP Best Practices: Options for Unsolicited Reporting, PDMP CTR. 
EXCELLENCE BRANDEIS UNIV. (May 2016), http://www.pdmpassist.org/ 
pdf/COE_documents/Add_to_TTAC/Update%20to%20Brandeis%20C
OE%20Guidance%20on%20Unsolicited%20Reporting%20final.pdf 
[hereinafter Options for Unsolicited Reporting]. 
212. Options for Unsolicited Reporting, supra note 211. 
213. See id. 
214. N.J. STAT. ANN. § 45:1-46(26) (West 2019). 
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receives prescriptions from a variety of prescribers, or visits a large 
number of pharmacies in a certain period, it may issue a report.215 
By facilitating enrollment and use through automated registration 
and educational programs, mandating PDMP use while also helping to 
balance clinical workflow by allowing users to delegate PDMP 
consultation, and sending automated reports, the uniform PDMP will 
ensure that prescribers and pharmacists alike are effectively utilizing 
this data resource. 
3. Conforming to the National Prescription Monitoring Information 
Exchange Architecture 
As of September 2017, forty-three states permitted PDMP 
interstate data-sharing on some level.216 But, due to a lack of 
uniformity, there is still insufficient access to all available PDMP 
data.217 To improve existing PDMPs, the uniform PDMP will require 
states to conform with PMIX to increase data sharing among states.218 
In order to participate in PMIX, states must: (1) have legislation 
allowing them to share patient information with authorized users in 
other states in real time; (2) identify at least one other state with which 
it desires to partner to exchange data; and (3) either establish a 
memorandum of understanding with its identified partner(s) or ratify 
the prescription monitoring interstate compact (“PMIC”).219 PMIC is 
an “agreement between two or more states for cooperative effort, 
mutual assistance, management, and regulation of [prescription opioid 
prescriptions] by the states, which transcend the boundaries of one 
state.”220 Moreover, any provisions within PMIC take precedence over 
conflicting and inconsistent laws of states.221 
If a state adopts the uniform PDMP, that state will have to adopt 
legislation that allows patient information to be shared with authorized 
users in other states in real time. The uniform PDMP will require states 
to share patient information with all other states who adopt the uniform 
PDMP by requiring states to join PMP InterConnect if they have not 
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already. By taking these steps, states will take significant steps toward 
successful interstate data-sharing. 
4. Counteracting Unintended Consequences 
Another issue facing the uniform PDMP is whether and how to 
allow law enforcement access. A majority of states, for obvious reasons, 
allow pharmacists and prescribers to access PDMP information related 
to their patients.222 But some states also allow other entities such as law 
enforcement to access the information.223 Prescribers typically object to 
PDMPs that permit this type of access because they see these programs 
as placing law enforcement above healthcare and patient treatment.224 
Their fear is not unwarranted. If law enforcement and licensing agencies 
have access to PDMP files without presenting probable cause or 
overcoming reasonable restrictions, PDMPs could turn into instruments 
used to sniff out criminal conduct and not be embraced by the medical 
community.225 
To ensure that prescribers are entitled to use their best judgment 
in creating treatment plans for patients in need, the uniform PDMP 
will adopt an approach similar to that of the Oregon PDMP.226 The 
uniform PDMP will require that any federal, state, or local law 
enforcement agency that wishes to have access to PDMP data be 
engaged in an authorized drug-related investigation of a specific 
individual.227 The uniform PDMP will require that the law enforcement 
agency submit a request form that specifies the information requested 
and a copy of a valid court order based on probable cause.228 Once the 
agency submits the form, it is up to the Board to review the request 
and determine whether or not to provide the agency with the requisite 
information. 229 
Allowing the Board to review law enforcement requests will strike 
the proper balance between facilitating drug investigations and 
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protecting doctor/patient autonomy and permit PDMP goals to remain 
intact.230 
5. Additional Measures to Bolster the Effectiveness of the Uniform 
PDMP 
Aside from the issues that commonly plague PDMPs, there are 
additional improvements that can be made. In addition to the 
previously mentioned policy changes, the uniform PDMP will expand 
the number of drug schedules monitored by the program.231 Drugs and 
the substances or other chemicals used to make them are placed into 
one of five schedules. The drug, substance, or chemical is classified into 
a certain schedule after the drug’s acceptable medical uses, and 
potential for abuse or dependency are analyzed.232 Lower numbered 
schedules are associated with a higher risk drug, for example, schedule 
one drugs are illegal and have no accepted medical uses.233 Opioids tend 
to fall within schedules two and four,234 therefore because studies show 
that the more schedules monitored by a state PDMP, the lower the 
rate of opioid-related overdose deaths, the uniform PDMP will require 
that states also monitor drugs that fall within schedules two through 
five. This means that the uniform PDMP will monitor all drugs with 
accepted medical uses that are subject to potential abuse.235 
The uniform PDMP will also require authorized users, primarily 
prescribers and pharmacists, to input data more frequently. But, to 
minimize any potential burden, prescribers and pharmacists will be 
required to upload information into the database at set, daily 
intervals.236 It is important that these users upload data no later than 
 
230. See Haffajee, supra note 120, at 1662. 
231. See Prescription Drug Monitoring Programs Linked to Reductions in 
Opioid Overdose Deaths, supra note 153; see also, 105 MASS. CODE REGS. 
§ 700.004(G)(1) (2018). 
232. Drug Schedules, U.S. DRUG ENF’T ADMIN., https://www.dea.gov/drug-
scheduling (last visited Mar. 16, 2018). 
233. Id. 
234. Id. 
235. Prescription Drug Monitoring Programs, CONG. RESEARCH SERV. (May 
24, 2018), https://www.everycrsreport.com/reports/R42593.html; see 
e.g., H.B. 150, 2013 Gen. Assemb., Reg. Sess. (Ala. 2013); 105 MASS. 
CODE REGS. § 700.004(G)(1) (2018); see USING THE PDMP TO OPTIMIZE 
PAIN MANAGEMENT, PA. PRESCRIPTION DRUG MONITORING PROGRAM 
SYSTEM USER AND STAKEHOLDER TRAINING (2017), available at 
https://www.health.pa.gov/topics/Documents/Programs/PDMP/3-
PDMP_UsingPMDP-Guide_F.pdf. 
236. See e.g., 902 KY. ADMIN. REGS. 55:110 § 2 (2019); See also 14-118-11 ME. 
CODE. R. § 5(C)(1) (LexisNexis 2017). 
Health Matrix·Volume 29·Issue 1·2019 
50 Shades of Data Sharing:  How a Uniform Fifty-State Prescription Drug 
Monitoring Program Can Restore Discretion to Opioid Prescribers and 
Autonomy to Chronic Pain Patients 
499 
midnight on the day on which the prescription was written and the day 
it was filled, because these users are responsible for supplying the 
uniform PDMP with essential data. However, these users may file for 
an extension if needed. Users responsible for inputting data may file for 
an extension within twenty-four hours after discovering either: (1) a 
mechanical or electrical failure; or (2) a reason beyond the user’s control 
that prevents the user from inputting data on time.237 The user must 
submit the extension request to the Board who should then issue a 
response within twenty-four hours. If the request falls within either of 
the above stated categories, the Board should grant the extension and 
the user will be free from penalties. But, if the Board denies the 
extension, absent the user self-reporting the necessary data, the user 
will be subject to penalties for failing to upload PDMP data in a timely 
manner.238 
By making additional modifications, the uniform PDMP will 
protect the autonomy of chronic pain patients, the discretion of doctors, 
and may even save the lives of opioid abusers. However, the 
improvement should not end here. The uniform PDMP should operate 
with as much flexibility as possible – allowing it to change as required 
to serve its purpose in combatting the opioid epidemic as well as the 
chronic pain population. The Board should remain vigilant in 
monitoring opioid-related statistics and make changes to the program 
as needed to ensure that the system achieves its overall goals. 
6. How Does This Fix the Problem? 
There are numerous issues that contribute to the undertreatment 
of pain in the United States, however two of the most serious obstacles 
to proper pain management are legal and societal.239 Restrictive laws, 
regulations, and guidelines surrounding prescription opioids have led to 
confusion about the appropriate role of opioids in pain management 
and put pressure on physicians to constrain prescribing.240 As a result, 
many physicians, out of fear of fueling the ever-worsening epidemic, 
began asking chronic pain patients who receive opioids to sign “pain 
contracts.”241 If a patient signs this contract, he is agreeing to only 
obtain medication from one doctor, submit to random drug screens and 
pill counts, and not to engage in any criminal activity which may 
include, but is not limited to using heroin or selling prescription 
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drugs.242 There is little evidence that the contracts work to deter 
prescription drug diversion, however they do work to further restrict 
legitimate access. However, the uniform PDMP provides a method by 
which to reduce these issues. The PDMP can be used to solve the 
continuing undertreatment problem by reducing the need for 
burdensome and restrictive government action while ensuring that 
those who need prescription opioids actually receive them.243 
The uniform PDMP will first reassure physicians that opioids have 
a legitimate place in the realm of pain management. The uniform 
PDMP will provide an efficient method by which physicians can 
effectively manage, improve, and change pain management strategies. 
In doing so, the uniform PDMP will guarantee that chronic pain 
patients are receiving the medications they need while also facilitating 
discussions about alternative pain management. The uniform PDMP 
can also assist physicians in developing a patient’s medical history 
which in turn supports patient safety.244 Because the PDMP will serve 
as an interface for opioid prescription data, a physician will have access 
to a patient’s previous prescriptions and be able to determine whether 
the patient needs an increased or decreased dosage, or whether the 
patient may need to seek help if they are exhibiting dangerous or 
addictive tendencies. Similarly, because the PDMP serves as a 
monitorable interface, physicians will be able to readily identify drug-
seeking behavior and thereby reduce doctor-shopping, diversion of 
controlled substances, and assist in other elements used to curb the 
abuse of prescription opioids, thereby eliminating the need for 
restrictive legislation, regulation, and guidelines that serve to harm the 
chronic pain population. 
IV. Conclusion 
Beginning in the 1990s, the United States has fallen victim to the 
opioid epidemic. Since then, state legislatures have searched for a 
comprehensive solution.245 However, state actions have failed to strike 
the necessary balance. Recent judicial, regulatory, and legislative steps 
created an overtly restrictive regime that impeded physician discretion 
and patient autonomy.246 It seems as though legislators failed to 
consider the importance of medical decision-making when trying to 
create a comprehensive approach to battling the opioid epidemic. 
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Moreover, recent legislative approaches have prevented chronic pain 
patients accessing much needed opioid prescriptions.247 In addition to 
already existing public health crisis related to the undertreatment of 
pain, restrictive state approaches added additional hurdles for these 
patients to access prescription opioids. 
However, many states took a step in the right direction by 
implementing PDMPs. In doing so, states provided prescribers and 
pharmacists with useful tools to detect abuse, misuse, drug diversion, 
and other illicit drug practices. However, these programs lacked 
uniformity and were riddled with issues such as inadequate data 
collection, ineffective utilization of data, insufficient interstate data-
sharing, and other unintended consequences. Therefore, despite taking 
an initial step in the right direction, state action has halted until a 
solution is implemented. 
Fortunately, a solution can be found by means of a uniform PDMP. 
The uniform PDMP will build upon current state PDMPs by using 
promising practices. The new system will ensure that data is used 
effectively and efficiently by prescribers and pharmacists while quelling 
physicians’ sanction-related fears. If states adopt the uniform PDMP 
and use it in conjunction with other less-restrictive measures adopted 
to combat the epidemic, the entire regime will equate to a promising 
step toward combating, and possibly ending, the opioid epidemic 
entirely. Lastly, and most importantly, if states adopt the uniform 
PDMP, physicians’ discretion and patient autonomy will be restored to 
pre-epidemic levels that conform to the rights owed to both parties. 
Overall, by adopting the uniform PDMP in its entirety, states have the 
ability to strike a required, and much needed, balance between medical 
decision-making, patient access, and combatting the opioid epidemic. 
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